Neoplasms

Nervous System Diseases

All Conditions

Brain Neoplasms

Supratentorial Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

All Drugs and Chemicals

Anti-Arrhythmia Agents

Adjuvants, Anesthesia

Respiratory System Agents

Neostigmine

Rocuronium

Atropine

Neuromuscular Blocking Agents

Cholinesterase Inhibitors

Enzyme Inhibitors

Cholinergic Agents

Neurotransmitter Agents

Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs

Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs

At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S

Sugammadex

At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously

Sherif A Mousa

Cholinesterase inhibitors such as Neostigmine and Edrophonium have been used to reverse neuromuscular blockade after surgery. However, these drugs have a relatively slow onset and have adverse effects associated with stimulation of muscarinic receptors. In addition, neostigmine cannot be used to reverse profound blockade.

Anesthetics may exert their effects on various facets of cerebral function such as cerebral metabolic rate (CMRO2), cerebral blood flow (CBF), cerebral blood flow-metabolism coupling, intra cranial pressure (ICP), autoregulation, vascular response to CO2 and brain electrical activity. The net result of all these effects of the anaesthetic agents combined with their systemic effects may prove beneficial or detrimental to an already diseased brain.

In neurosurgical patients, clear and rapid recovery is required to early assess the neurological status and to maintain the cerebral oxygenation and metabolism within the normal physiological values which may be saved by sugammadex.

The aim of this study is to compare Sugammadex versus neostigmine as a reversal to the neuromuscular blockade of rocuronium in patients undergoing supratentorial tumors resection. Comparison will include hemodynamics, respiratory effort and degree of sedation.

Indicators of global cerebral oxygenation and haemodynamics will be calculated using jugular bulb and peripheral arterial blood sampling.

Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine

Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium Neuromuscular Blockade In Cases Of Supratentorial Tumors: A Comparative Study Between Sugammadex Versus Neostigmine

The time from start of administration of sugammadex or neostigmine to recovery of the train-of-four (TOF) ratio to 0.9

eCMRO2=Ca- jO2 x(PaCO2 ∕ 100) Where ....... Ca jO2 is arterio-jugular O2 content difference.

* PaCO2 is arterial CO2 tension

Calculated as the differences between arterial and jugular bulb O2 saturations, CEO2 = SaO2 - SjvO2

Which is an index of flow metabolism relationship, calculated as a reciprocal of arterio-jugular O2 content difference

the time of restoration of neuromuscular conduction sufficient for extubation from stoppage of anaesthesia till the patient can obey commands

Time from start of administration of sugammadex or neostigmine to recovery of the train-of-four (TOF) ratio to 0.9

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine	NCT02944175	Supratentorial ...	Sugammadex Neostigmine	20 Years - 60 Years	Mansoura University
Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine	NCT02944175	Supratentorial ...	Sugammadex Neostigmine	20 Years - 60 Years	Mansoura University

Spots Global Cancer Trial Database for supratentorial brain tumor surgery